Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting

On September 21, 2020

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Examining the Effectiveness of Indexing Small Caps

Boeing, NASA Complete First Starliner Space Station Flight Test

Northrop Grumman Australia Announces Tech Showcase Winners